You are here

Article Text

Article menu
Download PDFPDF
PostScript
Group B streptococcus and preventive strategies in Europe
  1. A Berardi1,2,3,4,
  2. L Lugli1,2,3,4,
  3. C Rossi1,2,3,4,
  4. M S Morini1,2,3,4,
  5. F Vagnarelli1,2,3,4,
  6. F Ferrari1,2,3,4
  1. 1
    Unitè Operativa di Neonatologia, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
  2. 2
    Unitè Operativa di Pediatria, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy
  3. 3
    Unitè Operativa di Pediatria, Ospedale Pierantoni, Forlì, Italy
  4. 4
    Unitè Operativa di Neonatologia, Azienda Ospedaliera S Maria Nuova, Reggio Emilia, Italy
  1. A Berardi, Unitè Operativa di Neonatologia, Dipartimento Materno-Infantile, Azienda Ospedaliero-Universitaria Policlinico di Modena, Italy; berardi.alberto{at}policlinico.mo.it

https://doi.org/10.1136/adc.2007.135392

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We found Trijbels-Smeulders and coworkers epidemiology report very interesting.1 They studied early and late onset neonatal group B streptococcal (GBS) disease in the Netherlands before and after the introduction of guidelines for prevention. The best strategy in European countries is still a matter of debate and we need data which will allow reliable comparisons to be made between countries. In the USA the rate of early onset disease (EOD) has decreased markedly from 1.7/1000 to 0.34/1000 livebirths (70% reduction) after the adoption of guidelines and use of antibiotic prophylaxis.2 In contrast, the incidence of EOD is lower in the UK (0.48/1000 live …

    View Full Text

    Footnotes

    • Competing interests: None.